Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study

ObjectiveThis study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).MethodsFifty-five patients with pMN treated with obinutuzumab were respectively enrolled in this study. Clinical and immunologic...

Full description

Saved in:
Bibliographic Details
Main Authors: Xi Cheng, Zhen-feng Zheng, Yan Qi, Xin Cao, Xi-qian Gao, Ying-xin Fang, Li Wei, Wen-ya Shang, Tie-kun Yan, Jun-ya Jia, Peng-cheng Xu, Qiu-hua Gu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
membranous nephropathy
obinutuzumab
rituximab
anti-phospholipase A2 receptor antibody
renal function
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1650054/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1650054/full

Similar Items